We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA’s Office of Prescription Drug Promotion wants to know how consumers perceive drugmakers’ comparisons of pricing and efficacy information in advertisements. Read More
The Centers for Medicare & Medicaid Services has announced that it plans to begin paying for biosimilars through its Part B, Part D and state coverage policies by this summer. Read More
Generics makers may soon have a new way to challenge first-filer marketing exclusivity held by their rivals under certain circumstances after a federal appeals court reinstated a lawsuit from Apotex. Read More
Médecins Sans Frontières is urging Indian generics makers to reject a program Gilead plans to implement in developing countries to prevent illegal diversion of its hepatitis C drugs to more lucrative markets. Read More
Boehringer Ingelheim and Teva were again accused of blocking generic competition to the brandmaker’s antistroke drug Aggrenox just days after their bid to toss a similar lawsuit was denied. Read More
A federal judge has given the go-ahead to a class action lawsuit alleging Boehringer Ingelheim and Teva conspired to put off generic competition to the antistroke drug Aggrenox. Read More
Generics maker Sandoz will pay out $12.64 million to settle accusations it misrepresented average sales price information in reports to Medicare. Read More
Generics maker Glenmark might have infringed on Merck’s Indian patent covering type II diabetes drugs Januvia and Janumet, the Delhi High Court in India said recently in an interim ruling. Read More